Search | Engineering

Subscribe Submit

Home Journals Focus Achievement Fronts About Us 中文版

Resource Type

Journal Article 36

Conference Information 1

Conference Videos 1

Year

2023 3

2022 4

2021 6

2020 3

2019 11

2018 3

2017 2

2012 2

2011 1

2010 1

2009 1

2007 1

open ︾

Keywords

immunotherapy 17

cancer immunotherapy 4

hepatocellular carcinoma 4

immune checkpoint inhibitor 4

tumor immunotherapy 4

Cancer 3

Immunotherapy 3

genetic modification 3

targeted therapy 3

tumor microenvironment 3

PD-1 2

PD-L1 2

chimeric antigen receptor 2

natural killer cell 2

review 2

4-1BB ligand 1

Akkermansia muciniphila 1

B-cell acute lymphoblastic leukemia 1

B-cell lymphoma 1

open ︾

Search scope:

排序： Display mode:

Prospects of immunotherapy for cancer

Zhinan Chen

Frontiers of Medicine 2019, Volume 13, Issue 1, Pages 1-2 doi: 10.1007/s11684-019-0691-y

Abstract:

HTML PDF Collect

Immunometabolism: a new dimension in immunotherapy resistance

Frontiers of Medicine 2023, Volume 17, Issue 4, Pages 585-616 doi: 10.1007/s11684-023-1012-z

Abstract: tumor-infiltrating immunocytes could offer fresh opportunities to break the resistance and ameliorate existing ICI immunotherapyHerein, we elaborate potential mechanisms underlying immunotherapy resistance from a novel dimension

Keywords： immune cell immunometabolism metabolic reprogramming immunotherapy resistance tumor microenvironment

HTML PDF Collect

Dendritic cell vaccines in cancer immunotherapy: from biology to translational medicine

Hongmei Xu, Xuetao Cao

Frontiers of Medicine 2011, Volume 5, Issue 4, Pages 323-332 doi: 10.1007/s11684-011-0172-4

Abstract:

HTML PDF Collect

Challenges of NK cell-based immunotherapy in the new era

Fang Fang, Weihua Xiao, Zhigang Tian

Frontiers of Medicine 2018, Volume 12, Issue 4, Pages 440-450 doi: tzg@ustc.edu.cn

Abstract:

Natural killer cells (NKs) have a great potential for cancer immunotherapy because they can rapidly

Keywords： natural killer cells immunotherapy adoptive transfer genetic modification immune checkpoint inhibitor

HTML Collect

CAR T-cell immunotherapy: a powerful weapon for fighting hematological B-cell malignancies

Frontiers of Medicine 2021, Volume 15, Issue 6, Pages 783-804 doi: 10.1007/s11684-021-0904-z

Abstract: Chimeric antigen receptor T-cell (CAR T) immunotherapy opens a new path for targeted therapy of hematological

Keywords： CAR T cells hematological malignancies review

HTML PDF Collect

Developing effective tumor vaccines: basis, challenges and perspectives

XU Qingwen, CHEN Weifeng

Frontiers of Medicine 2007, Volume 1, Issue 1, Pages 11-19 doi: 10.1007/s11684-007-0003-9

Abstract: these antigens, cancer/testis antigen (CT antigen) is considered to be the most promising target for immunotherapySuccessful immunotherapy of tumors requires understanding of the natural relationship between the immune

Keywords： development conventional identification elucidation Successful immunotherapy

HTML PDF Collect

Regulatory T Cells and Their Clinical Applications in Antitumor Immunotherapy Review

Feng Xie, Rui Liang, Dan Li, Bin Li

Engineering 2019, Volume 5, Issue 1, Pages 132-139 doi: 10.1016/j.eng.2018.12.002

Abstract: Immunotherapy has recently gained increasing interest among researchers due to its tremendous potential, there is renewed interest in the function of Tregs and in their clinical application in antitumor immunotherapy

Keywords： Regulatory T cells Cancer Immunotherapy

HTML PDF Collect

Radial porous SiO

Chuangnian Zhang, Ying Dong, Jing Gao, Xiaoli Wang, Yanjun Jiang

Frontiers of Chemical Science and Engineering 2021, Volume 15, Issue 5, Pages 1296-1311 doi: 10.1007/s11705-020-2034-6

Abstract: Here, we reported a cancer nanovaccine based on SiO nanoflowers with a special radial pore structure, which greatly enhanced cross-presentation and induced the production of cytotoxic T lymphocyte cells secreting granzymes B and interferon- . The antigen ovalbumin was covalently conjugated onto the as-synthesized hierarchical SiO nanoflowers, and the adjuvant cytosine-phosphate-guanine was electrostatically adsorbed into their radial pore by simple mixing before use. The nanovaccine exhibited excellent storage stability without antigen release after 27 days of incubation, negligible cytotoxicity to dendritic cells, and a high antigen loading capacity of 430±66 mg·g support. Besides, the nanovaccine could be internalized by dendritic cells via multiple pathways. And the enhancement of antigen/adjuvant uptake and lysosome escape of antigen were observed. Noteworthy, culture of bone marrow-derived dendritic cells in the presence of nanovaccine proved the activation of dendritic cells and antigen cross-presentation as well as secretion of proinflammatory cytokines. Besides, study verified the targeting of nanovaccine to draining lymph nodes, the complete suppression of tumor in six out of ten mice, and the triggering of notable tumor growth delay. Overall, the present results indicated that the nanovaccine can be served as a potential therapeutic vaccine to treat cancer.

Keywords： silica nanoflower antigen delivery cancer immunotherapy nanovaccine

HTML PDF Collect

and novel CD3/CD19/CD20 trispecific antibodies against B-cell acute lymphoblastic leukemia: targeted immunotherapy

Frontiers of Medicine 2022, Volume 16, Issue 1, Pages 139-149 doi: 10.1007/s11684-021-0835-8

Abstract: The CD19-targeting bispecific T-cell engager blinatumomab has shown remarkable efficacy in patients with relapsed/refractory B-cell precursor acute lymphoblastic leukemia. However, several studies showed that blinatumomab has a short plasma half-life due to its low molecular weight, and thus its clinical use is limited. Furthermore, multiple trials have shown that approximately 30% of blinatumomab-relapsed cases are characterized by CD19 negative leukemic cells. Here, we design and characterize two novel antibodies, A-319 and A-2019. Blinatumomab and A-319 are CD3/CD19 bispecific antibodies with different molecular sizes and structures, and A-2019 is a novel CD3/CD19/CD20 trispecific antibody with an additional anti-CD20 function. Our in vitro, ex vivo, and in vivo experiments demonstrated that A-319 and A-2019 are potent antitumor agents and capable of recruiting CD3 positive T cells, enhancing T-cell function, mediating B-cell depletion, and eventually inhibiting tumor growth in Raji xenograft models. The two molecules are complementary in terms of efficacy and specificity profile. The activity of A-319 demonstrated superior to that of A-2019, whereas A-2019 has an additional capability to target CD20 in cells missing CD19, suggesting its potential function against CD19 weak or negative CD20 positive leukemic cells.

Keywords： B-cell acute lymphoblastic leukemia bispecific antibody trispecific antibody CD19 CD20

HTML PDF Collect

Activation of phagocytosis by immune checkpoint blockade

Chia-Wei Li, Yun-Ju Lai, Jennifer L. Hsu, Mien-Chie Hung

Frontiers of Medicine 2018, Volume 12, Issue 4, Pages 473-480 doi: 10.1007/s11684-018-0657-5

Abstract:

Inhibition of macrophage-mediated phagocytosis has emerged as an essential mechanism for tumor immune evasion. One mechanism inhibiting the innate response is the presence of the macrophage inhibitory molecule, signal regulatory protein-α (SIRPα), on tumor-associated macrophages (TAMs) and its cognate ligand cluster of differentiation 47 (CD47) on tumor cells in the tumor microenvironment. On the basis of a recently discovered programmed death protein 1 (PD-1) in TAMs, we discuss the potential inhibitory receptors that possess new functions beyond T cell exhaustion in this review. As more and more immune receptors are found to be expressed on TAMs, the corresponding therapies may also stimulate macrophages for phagocytosis and thereby provide extra anti-tumor benefits in cancer therapy. Therefore, identification of biomarkers and combinatorial therapeutic strategies, have the potential to improve the efficacy and safety profiles of current immunotherapies.

Keywords： CD47 PD-1 PD-L1 immunotherapy TAM phagocytosis macrophage

HTML PDF Collect

Natural Killer Cell-Based Immunotherapy for Cancer: Advances and Prospects Review

Yuan Hu, Zhigang Tian, Cai Zhang

Engineering 2019, Volume 5, Issue 1, Pages 106-114 doi: 10.1016/j.eng.2018.11.015

Abstract: of tumor escape from NK cell recognition, the current status and advanced progress of NK cell-based immunotherapy

Keywords： Natural killer cell Immunotherapy Cancer Clinical trial Chimeric antigen receptor

HTML PDF Collect

Translational medicine in hepatocellular carcinoma

Qiang Gao, Yinghong Shi, Xiaoying Wang, Jian Zhou, Shuangjian Qiu, Jia Fan

Frontiers of Medicine 2012, Volume 6, Issue 2, Pages 122-133 doi: 10.1007/s11684-012-0193-7

Abstract: In addition, we examine the potential of immunotherapy and strategies targeting various components of

Keywords： hepatocellular carcinoma molecular classification molecular targeted therapies tumor microenvironment immunotherapy

HTML PDF Collect

Prospect of Medical Disruptive Technologies

Li Yongjie, Yang Juntao, Du Jian

Strategic Study of CAE 2018, Volume 20, Issue 6, Pages 64-68 doi: 10.15302/J-SSCAE-2018.06.010

Abstract: This paper mainly analyzes and evaluates five technical directions in tumor immunotherapy, gene editing

Keywords： medical technology disruptive technology tumor immunotherapy gene editing

HTML PDF Collect

Emerging immunological strategies: recent advances and future directions

Frontiers of Medicine 2021, Volume 15, Issue 6, Pages 805-828 doi: 10.1007/s11684-021-0886-x

Abstract: Immunotherapy plays a compelling role in cancer treatment and has already made remarkable progress.This review explores the recent progress and challenges of different forms of immunotherapy agents and

Keywords： cancer immunotherapy bispecific antibodies small molecules chimeric antigen receptor T therapy cancer